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Summary
Background.— Intrastent thrombosis, while rare, has a poor prognosis. Strut non-coverage is
one causal factor, especially in cases of resistance to or premature discontinuation of dual
antiplatelet therapy.
Aim.— To compare neointimal coverage with paclitaxel and zotarolimus drug-eluting stents,
using optical coherence tomography (OCT).
Methods.— Twenty-two drug-eluting stents (11 paclitaxel-eluting stents and 11 zotarolimus-
eluting stents) were examined by OCT, 6months after implantation. Mean neointimal
strut-coverage thickness and percentage neointimal hyperplasia were measured every millime-
tre. On each OCT image, struts were classiﬁed into one of four categories: well-apposed to
vessel wall with apparent neointimal coverage; well-apposed to vessel wall without neointimal
coverage; malapposed to the vessel wall; or located on a major side branch.
Abbreviations: DES, Drug-eluting stent; LA, Lumen area; OCT, Optical coherence tomography; PES, Paclitaxel-eluting stent; SA,
Stent area; ZES, Zotarolimus-eluting stent.
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Conclusion.— La prolifération néo-intimale est plus importante après implantation d’un stent
au zotarolimus qu’avec les stents au paclitaxel. Elle s’accompagne à six mois d’une meilleure
rvée
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andomized studies have shown that drug-eluting stents
DESs) reduce clinical restenosis rates signiﬁcantly com-
ared with bare-metal stents [1—4] due to inhibition of
ntimal neoproliferation [5]. Animal and autopsy studies,
owever, have shown this effect to be associated with
elayed or deﬁcient re-endothelialization. It is therefore
dvisable to continue dual antiplatelet therapy beyond the
rst month poststenting to avoid the extreme danger of late
ntrastent thrombosis [6]. In a series of 8000DESs, Daemen
t al. reported a consistent 0.6% late thrombosis rate over
he ﬁrst 3 years poststenting [7].
Intrastent thrombosis is a multifactorial phenomenon [8],
ut one signiﬁcant factor is the failure of stent—strut re-
ndothelialization [9]. Postmortem studies of stented sub-
ects [10] have reported that deﬁcient re-endothelialization
s associated more frequently with late intrastent thrombo-
is than with other causes of death [11,12].
Angioscopy has been the only in vivo imaging technique
vailable for studying re-endothelialization, but it does not
nable quantiﬁcation [9,13]. Angiography sheds light only
n restenosis, while intravascular ultrasound imaging lacks
ufﬁcient resolution to reveal stent coverage accurately.
ptical coherence tomography (OCT) is a high-resolution
around 10m) imaging technology that is particularly well
dapted for the study of the most superﬁcial layers of the
a
s
nen tomographie par cohérence optique.
s droits réservés.
essel wall and for strut-by-strut stent analysis. Several
ecent studies have focused on OCT analysis of neointimal
overage in bare-metal and ﬁrst-generation drug-eluting
sirolimus) stents [14—17].
In this study, we used OCT to compare neointimal cov-
rage at 6months poststenting with two types of DES:
paclitaxel-eluting stent (PES) and a zotarolimus-eluting
tent (ZES).
ethods
tudy population
etween October 2006 and September 2007, 19 patients (16
en, 3 women) were included in the study. These patients
ere selected from the 790 patients treated in our centre,
sing the following inclusion criteria: consent, feasibility of
CT and DES indication. After randomization, the patients
eceived a DES in a native coronary artery: 11 paclitaxel-
luting stents (PESs) and 11 zotarolimus-eluting stents
ZESs). Exclusion criteria were left main coronary arteryP. Motreff et al.
Results.— OCT analysis showed a lower percentage of neointimal hyperplasia with paclitaxel-
eluting stents than with zotarolimus-eluting stents (17% vs 38% and mean thickness 154m
vs 333m, respectively; p < 0.0001). The rate of strut-coverage was greater with zotarolimus-
eluting stents than with paclitaxel-eluting stents (99.1% vs 87.1%, respectively; p < 0.0001). A
non-covered/covered strut ratio greater than 0.3 was observed in 0.5% of zotarolimus-eluting
stent OCT images compared with 18% of paclitaxel-eluting stent OCT images (p < 0.0001).
Conclusion.— Six months after implantation, neointimal hyperplasia was greater with
zotarolimus-eluting stents compared with paclitaxel-eluting stents. Conversely, neointimal
strut-coverage was better with zotarolimus-eluting stents.
© 2009 Elsevier Masson SAS. All rights reserved.
Résumé
Contexte.— La thrombose de stent reste un évènement rare mais de mauvais prognostic. Un des
facteurs est l’absence de réendothélialisation des stents, notamment en présence de résistance
ou d’arrêt prématuré du traitement antiagrégant plaquettaire.
Objectif.— Comparer l’hyperplasie néointimale à six mois de stents actifs au paclitaxel et au
zotarolimus en imagerie par cohérence optique.
Méthode.— Vingt-deux stents actifs ont été analysé en imagerie par cohérence optique : 11
au paclitaxel et 11 au zotarolimus six mois après leur implantation. L’épaisseur moyenne de la
néo-intima est mesurée tous les millimètre ainsi que le pourcentage d’hyperplasie néointimale.
Chaque maille est qualiﬁée de couverte, non couverte, malapposée ou en regard de collatérale.
Résultats.— L’analyse OCT retrouve un pourcentage d’hyperplasie néo-intimale moindre dans
le groupe paclitaxel : 15 % versus 38 % avec une épaisseur moyenne de 154m versus 333m,
respectivement; p < 0,0001. Les mailles sont plus souvent couvertes dans le groupe zotarolimus
(99,1 % vs 87,1 %, p < 0,0001). Un ratio nombre de mailles non couvertes/couvertes supérieur à
0,3 est retrouvé sur 0,5 % des coupes de stents au zotarolimus (un des 11 stents) vs 18 % dans le
groupe paclitaxel (sept des 11 stents) (p < 0,0001).cute-phase infarction and contraindication to a DES.
An angiographic control was scheduled at 6months post-
tenting. Restenosis was deﬁned as greater than 50% lumen
arrowing on angiography.
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Figure 1. Drug-eluting stent analysis on optical coherence tomography millimetric images: top, qualitative strut analysis. A. Covered.
B. Non-covered. C. Malapposed. D. Facing collateral. Bottom, quantitative analysis: intrastent area (green), lumen area (red), coverage
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Optical coherence tomography procedure
OCT was conducted 6months after stenting, immedi-
ately after the control angiography. Unfractionated heparin
(30 IU/kg) was injected intra-arterially via a 6F catheter. A
0.014-inch guide was introduced into the vessel and posi-
tioned distally to the stent. A HeliosTM coaxial occlusion
balloon catheter (LightLab Imaging, Westford, MA, USA) was
then introduced along the guide across the vessel until the
balloon marker was at the distal extremity of the stent. The
guide was withdrawn and replaced by a 1.4F optic ﬁbre,
connected to the occlusion balloon catheter and inserted
through the balloon until distal to the stent. The occlusion
balloon was then withdrawn until proximal to the DES and
inﬂated to between 0.4 and 0.7 atm. Physiological saline
was injected downstream of the occlusion balloon catheter
via its coaxial catheter; 30mL were injected during each
pullback. OCT gives a clear image once the medium is suf-
ﬁciently transparent. Automatic light-source pullback then
began (1mm/s, with 15 images per second acquisition).
A 30mm DICOM-format video recording was made of the
artery, including the stented segment. The balloon was then
deﬂated and the saline injection stopped. Several pullbacks
may be needed for analyses exceeding 30mm. The pullbacks
were repeated until perfect visualization of the whole length
of all stents was obtained.
Optical coherence tomography analysis
OCT images were selected from the DICOM pullback record-
ings every millimetre (every 15 images) over the entire
stented segment and analysed by two independent opera-
tors. Lumen area (LA, in mm2) and stent area (SA, in mm2)
were measured on each image, to enable calculation of the
percentage neointimal hyperplasia area (SA-LA/SA× 100).
n
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Ieointimal hyperplasia thickness was measured on each
trut (Fig. 1). The struts visible in each image were classiﬁed
nto four categories:A: well-apposed to the vessel wall with
pparent neointimal coverage;B: well-apposed to the vessel
all but without neointimal coverage (non-coverage deﬁned
s the absence of any visible structure between the lumen
nd vessel on OCT, with strut reﬂection);C: malapposed to
he vessel wall without neointimal coverage (malapposi-
ion deﬁned as > 110m between the reﬂection of the stent
trut and the vessel wall, corresponding to OCT axial reso-
ution + thickness of stent strut);D: in a bifurcation.
The percentage of covered struts per OCT image was
oted.
tatistical analysis
he data had a multilevel hierarchical structure. The PES
roup comprised 11 patients with 11 stents and the ZES group
ight patients with 11 stents; three patients in the ZES group
ith two stents each were individualized for analysis. In
erms of OCT images, there were 200 PES items and 195 ZES
tems; in terms of struts, there were 2511 PES items and
615 ZES items.
Quantitative variables are presented as mean± standard
eviation for the two groups. For qualitative variables, con-
ingency tables were drawn up for the study population as
whole. The rates for each coverage category were cal-
ulated for the total of 5126 struts and were treated as
ontinuous quantitative variables. The PES and ZES groups
ere compared in terms of the various variables by the
on-parametric Wilcoxon test for quantitative variables and
isher’s exact test for the 2× 2 tables of qualitative vari-
bles. All tests were conducted with a bilateral formulation,
ith ﬁrst-degree risk set at 5%, using SAS v9 software (SAS
nstitute, Cary, NC, USA).
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Table 1 Population characteristics.
Characteristic Paclitaxel (n = 11) Zotarolimus (n = 8) p
Patients
Age (years) 55.4± 11.9 59.4± 10.8 0.30
Men 9 7 1.00
Risk factors
Smoking 9 5 0.60
Diabetes 2 2 1.00
Hypertension 1 1 1.00
Hyperlipidaemia 7 5 1.00
Obesity 1 4 0.11
Heredity 2 1 1.00
Coronary history 2 2 1.00
Angina 1 1 1.00
Acute coronary syndrome 10 7
Glycoprotein IIb/IIIa inhibitor treatment 4 1 0.34
Location of stent (n = 11) (n = 11)
Left anterior descending coronary artery 6 4 0.75
Left circumﬂex coronary artery 3 4
Right coronary artery 2 3
Lesion type (American College of Cardiology/American Heart Association)
A 3 2 1.00
B1 5 5
B2 3 4
C 0 0
Reference lumen diameter (mm) 2.9± 0.3 3.0± 0.3 0.82
Minimal lumen diameter (mm) 0.7± 0.4 0.6± 0.4 0.60
Lesion length (mm) 14.6± 5.1 14.4± 6.3 0.77
Stent diameter (mm) 2.9± 0.2 3.1± 0.3 0.11
Stent length (mm) 18.2± 5.2 17.7± 6.9 0.79
Inﬂation pressure (atm) 12.7± 2.1 13.3± 2.2
Direct stenting 11 9
Postdilatation 0 1
Postangioplasty reference lumen diameter (mm) 3.0± 0.2 3.0± 0.3
Postangioplasty minimal lumen diameter (mm) 2.9± 0.2 2.9± 0.4
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Values are numbers or mean± standard deviation. p = non-signiﬁc
esults
opulation characteristics
opulation characteristics are given in Table 1. Most patients
nderwent angioplasty after a non-ST-segment elevation
cute coronary syndrome (17 patients). The two groups did
ot differ signiﬁcantly in terms of clinical characteristics or
esion type and all lesions were de novo. Stent diameters
anged from 2.5 to 4.0mm and lengths from 9 to 32mm.
here were no complications secondary to angioplasty dur-
ng the 6-month follow-up period under dual antiplatelet
herapy or during the OCT procedure.
ngiographic analysisefore angioplasty, there were no signiﬁcant inter-
roup differences in reference or minimum diameter:
.9± 0.3mm and 0.7± 0.4mm, respectively, in the PES
roup and 3.0± 0.3mm and 0.6± 0.40mm, respectively, in
w
c
w
c
e11
he ZES group (p = 0.82 and p = 0.60, respectively). Mean
esion length was 14.6± 5.1mm in the PES group and
4.4± 6.3mm in the ZES group (p = 0.77). At 6months, there
as no intrastent restenosis requiring further revasculariza-
ion.
ptical coherence tomography analysis
CT was performed in all 22 patients. Thirty-ﬁve pull-
acks were performed to analyse the 22 stents. In all,
95mm of stent were studied and 5126 struts were visu-
lized (200 PESOCT cross-sectional images, for 2511 struts;
95 ZES OCT cross-sectional images, for 2615 struts). Strut
overage thickness was estimated by two independent
perators. Concordance with quantitative measurements
as virtually perfect, with an intraclass correlation
oefﬁcient of 0.99. The value submitted to analysis
as the mean of the two observers’ estimates. Strut
overage was likewise classiﬁed in the four exclusive cat-
gories by the two independent observers, again with
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Table 2 Neointimal hyperplasia and strut coverage.
Paclitaxel Zotarolimus p
OCT images (n = 200) (n = 195)
Lumen area (mm2) 6.53± 2.20 5.09± 2.80 < 0.0001
Intrastent area (mm2) 7.78± 1.78 7.89± 2.83 0.64
Neointimal hyperplasia area (mm2) 1.25± 1.23 2.81± 1.09 < 0.0001
Proliferation rate (%) 17± 16 38± 15 < 0.0001
OCT images with > 70% covered struts 82.0 99.5 < 0.0001
Mean strut-cover thickness (mm) 0.154 ± 0.133 0.333 ± 0.147 < 0.0001
Struts (%) (n = 2511) (n = 2615)
Covered 87.1 99.1 < 0.0001
Non-covered 9.9 0.2 < 0.0001
Malapposed 1.8 0.4 0.012
S
(
ZFacing collateral 1.2
Values are mean± standard deviation or percentage.
virtually perfect agreement (kappa = 0.99). In cases of
disagreement, the category adopted for analysis was
determined by a third observer. Results are shown in
Table 2.
Neointimal thickness
Mean endothelial thickness was 154± 133m in the PES
group and 333± 147m in the ZES group (p < 0.0001) (Fig. 2).
g
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Figure 2. Distribution of strut coverage thickness in paclitaxel-eluting0.3 0.011
tent area did not differ signiﬁcantly between groups
7.78± 1.78mm2 in the PES group vs 7.89± 2.83mm2 in the
ES group; p = 0.64).Neointimal proliferation was greater in the ZES
roup, with a mean lumen area of 5.09± 2.80mm2 vs
.53± 2.20mm2 in the PES group (p < 0.0001) and a percent-
ge neointimal hyperplasia of 38± 15% versus 17± 16% in the
ES group (p < 0.0001).
stent (PES) and zacrolimus-eluting stent (ZES) groups.
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Figure 3. Examples of optical coherence tomography images. A. Paclitaxel-eluting stent, 3.0× 20mm, neointimal hyperplasia area 13%,
mean neointimal hyperplasia thickness 95m, 100% covered struts. B. Zacrolimus-eluting stent, 4.0× 9mm, neointimal hyperplasia area
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t6%, mean neointimal hyperplasia thickness 270m, 100% covered
rea 47%, mean neointimal hyperplasia thickness 375m, 100% c
aclitaxel-eluting stent, 6/19 struts non-covered, 68% covered. F. P
eointimal coverage
he incidence of non-covered struts was greater in the
ES group (12.9% vs 0.9%; p < 0.0001); there was also a
igher rate of malapposition in the PES group (1.8% vs 0.4%;
< 0.0001) (Fig. 3). Non-coverage of more than 30% of struts
er OCT image also occurred more frequently in the PES
roup (18% vs 0.5%; p < 0.0001). Seven PESs but only one ZES
ere associated with a covered/non-covered strut ratio of
reater than 0.3 on at least one OCT image. No thrombi were
bserved in any of the 22 examinations.
iscussion
ntrastent thrombosis is rare, but has an extremely serious
rognosis and a reported mortality reaching 45% [6,18,19].
trut non-coverage is one causal factor, especially in cases
f resistance to or premature discontinuation of dual
ntiplatelet therapy. There is, however, a lack of tools for
he in vivo study of re-endothelialization. For these pur-
oses, OCT would seem to be reliable, providing precise,
eproducible, strut-by-strut measurements. Our experience
as that interobserver variability was negligible and that all
mages were analysable in an appropriately selected popula-
ion. At 10m, resolution is excellent, individualizing each
trut.Initial OCT studies focused on endothelialization of
irolimus-eluting stents. Takano et al., studying 31 sirolimus-
luting stents 3months poststenting, reported a mean
eointimal thickness of 29m. The percentages of non-
overed and malapposed struts were 15 and 6%, respectively
e
o
s
t
as. C. Zacrolimus-eluting stent, 2.5× 8mm, neointimal hyperplasia
d struts. D. Paclitaxel-eluting stent, 2/11 struts malapposed. E.
axel-eluting stent, 2/12 struts facing collateral branch.
16]. Matsumoto et al., with 57 sirolimus-eluting stents
months poststenting, reported a mean neointimal thick-
ess of 52.5m and 8% non-covered struts, including 1%
alapposed [15]. Takano et al., after 2 years of follow-up of
1 patients with a sirolimus-eluting stent, reported a mean
eointimal thickness of 71m, with 5% of struts remaining
on-covered [17].
Our present study is the ﬁrst OCT comparison of neoin-
imal coverage between two types of DESs. The data show
reater neointimal hyperplasia at 6months in the ZES group
333m vs 154m in the PES group). In this short series,
eointimal hyperplasia did not lead to angiographic resteno-
is, but did result in almost total strut coverage in the
ES group, in agreement with previous angiographic ﬁnd-
ngs based on late-loss. Pocock et al., in 11 randomized
rials, reported less than 0.21mm late-loss with sirolimus-
luting stents, between 0.30mm and 0.49mm with PESs,
etween 0.60 and 0.61mm with ZESs, and between 0.80
nd 1.06mm with bare-metal stents [20]. There is a curvilin-
ar correlation between late-loss and reintervention rates,
ith a low incidence of clinical events when late-loss is
ess than 0.65mm [21]. This may account for the lack of
bserved clinical beneﬁt in studies that compared different
ESs. Like angiography, OCT disclosed greater neointimal
yperplasia with ZESs than with PESs. On the other hand,
igniﬁcantly fewer non-covered struts were found with ZESs
han with PESs. Postmortem series conﬁrm that lack of
ndothelial strut coverage is the prime histological predictor
f late thrombosis: the relative risk of intrastent thrombo-
is increases ninefold in cases of non-coverage of greater
han 30% of struts per OCT image [11]. Takano et al. [17],
pplying this prognostic index in an OCT study, found 38% of
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patients with a sirolimus-eluting stent presenting with this
thrombosis risk factor, 2 years poststenting. In our present
study, this was the case in 64% of PES patients and 9% of ZES
patients, 6months poststenting.
In the literature, there was a signiﬁcant difference
between the rate of late thrombosis in the DES era (< 1% per
year) and the rate of deﬁcient coverage observed in vivo on
OCT, even at 2-year follow-up. Thus, non-coverage is not a
sufﬁcient condition for the development of late thrombosis,
but may be a determining risk factor when associated with
others, such as premature discontinuation of antiplatelet
therapy. These ﬁndings lead us to continue dual antiplatelet
therapy beyond the ﬁrst 6months after DES stenting in
patients who do not have a high risk of haemorrhage, in
line with the latest guidelines [22—24]. Some studies have
indeed reported that termination of clopidogrel treatment
at 6months post-DES-stenting was associated with increased
late thrombosis and elevated mortality rates [24,25]. Our
present study and previous studies show OCT to be an
adapted tool for quantifying stent re-endothelialization and
partial strut coverage with safety [26]. Future randomized
comparative OCT trials may provide prognostic factors shed-
ding light on poststenting healing and help to determine the
optimal course of dual antiplatelet therapy. The correlation
between the number of non-covered struts and the risk of
late thrombosis still requires validation, however, in a larger
prospective study.
Our study has a number of limitations. The sample size
was small and from a single centre. OCT itself involves
certain limitations: it requires transitory occlusion of the
coronary artery, precluding analysis of the most proximal
segments; currently, it does not have sufﬁcient resolution to
rule out the beginnings of re-endothelialization in the form
of a 5-m thick cellular monolayer; ﬁnally, tissue character-
ization is not always straightforward, hence the structure
covering certain struts may be taken for neoproliferation,
when it is, in fact, simply ﬁbrin. Technological progress can
be expected to alleviate these limitations.
Conclusion
OCT provides precise measurement of intimal hyperplasia
volume and neointimal coverage of stent struts. The present
comparative study found better strut re-endothelialization
with zotarolimus stenting than with paclitaxel stenting, at
the cost of greater mean hyperplasia—although not enough
to cause restenosis.
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